首页> 外文期刊>Analytical and bioanalytical chemistry >A novel UPLC-MS-MS method for simultaneous determination of seven uremic retention toxins with cardiovascular relevance in chronic kidney disease patients
【24h】

A novel UPLC-MS-MS method for simultaneous determination of seven uremic retention toxins with cardiovascular relevance in chronic kidney disease patients

机译:一种新型的UPLC-MS-MS方法,可同时测定慢性肾脏病患者中与心血管相关的七种尿毒症retention留毒素

获取原文
获取原文并翻译 | 示例
       

摘要

Chronic kidney disease (CKD) is a devastating illness characterized by accumulation of uremic retention solutes in the body. The objective of this study was to develop and validate a simple, rapid, and robust UPLC-MS-MS method for simultaneous determination, in serum, of seven organic acid uremic retention toxins, namely uric acid (UA), hippuric acid (HA), indoxylsulfate (IS), p-cresylglucuronide (pCG), p-cresylsulfate (pCS), indole-3-acetic acid (IAA), and 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF). Isotopically labeled internal standards (d_5-HA; 1,3-~(15)N_2-UA, and d_5-IAA) were used to correct for variations in sample preparation and system performance. Separation on a C18 column was followed by negative electrospray ionization and tandem mass spectrometric detection. Accuracy was below the 15 % threshold. Within-day precision varied from 0.60 to 4.54 % and between-day precision was below 13.33 % for all compounds. The applicability of the method was evaluated by analyzing 78 serum samples originating both from healthy controls and from patients at different stages of CKD. These results were compared with those obtained by use of conventional HPLC-PDA-FLD methods. A good correlation was obtained between both methods for all compounds.
机译:慢性肾脏病(CKD)是一种破坏性疾病,其特征是尿毒症保留溶质在体内积累。这项研究的目的是开发和验证一种简单,快速且可靠的UPLC-MS-MS方法,用于同时测定血清中的7种有机酸尿毒症保留毒素,即尿酸(UA),马尿酸(HA) ,吲哚基硫酸盐(IS),对甲酚基葡萄糖醛酸(pCG),对甲酚基硫酸盐(pCS),吲哚-3-乙酸(IAA)和3-羧基-4-甲基-5-丙基-2-呋喃丙酸(CMPF) 。同位素标记的内部标准品(d_5-HA; 1,3-〜(15)N_2-UA和d_5-IAA)用于校正样品制备和系统性能的变化。在C18色谱柱上进行分离后,进行负电喷雾电离和串联质谱检测。准确性低于15%的阈值。所有化合物的日内精度在0.60%至4.54%之间变化,日间精度低于13.33%。该方法的适用性通过分析来自健康对照和CKD不同阶段患者的78份血清样品进行评估。将这些结果与使用常规HPLC-PDA-FLD方法获得的结果进行了比较。对于所有化合物,两种方法之间均获得了良好的相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号